Abstract
Objective:
To compare bleeding complications in pregnant patients treated with low-molecular-weight heparin (LMWH) to untreated controls.
Study design:
A case–control study of patients from 2001 to 2005 who received prophylactic or therapeutic doses of LMWH during pregnancy was carried out. Indications for LMWH included current or prior thromboembolism, thrombophilia, or heart valve replacement. Controls were chosen in a 2:1 ratio to cases, matched for delivery route, and selected as the next two consecutive deliveries. The primary outcome was postpartum hemorrhage (PPH). Odds ratios (ORs) were calculated with 95% confidence intervals (CIs).
Results:
Forty-nine women treated with LMWH delivered 55 infants. Current or prior thromboembolic disease was the anticoagulation indication in 15/55 (27.3%) and 26/55 (47%) of pregnancies, respectively. There were more obese gravidas (OR 3.91, CI 1.70 to 9.09) and labor induction was more common in the LMWH group, 25/55 (45%) vs 29/110 (26%), P=0.01. There was no difference in estimated blood loss (295.7±145.7 vs 308.6±111.9 cm3, P=0.62 vaginal; 687.5±251.8 vs 765.0±313.2 cm3, P=0.34 cesarean), PPH (6/55, 11% vs 9/110, 8.2% OR 1.37, CI 0.16 to 11.5) or transfusion (3/55, 5.4% vs 4/110, 3.6% OR 1.50, CI 0.3 to 7.48) between the cases and controls. There were two cases of postpartum pulmonary emboli, one with a maternal mortality.
Conclusion:
Bleeding complications, including PPH and transfusion, in patients treated with LMWH during pregnancy were not increased when compared to normal controls matched for delivery route.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N et al. Thromboprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39–43.
Frydman A . Low-molecular-weight-heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26 (Suppl): 2:24–2:38.
Leizorovicz A, Simonneau G, Decousus H, Boissel JP . Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. Br Med J 1994; 309: 299–304.
Lensing AWA, Prins MH, Davidson BL, Hirsh J . Treatment of deep venous thrombosis with low molecular weight heparins: a meta-analysis. Arch Intern Med 1995; 155: 601–607.
Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS . Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269–277.
Dolovich L, Ginsberg JS . Low molecular weight heparin in the treatment of venous thromboembolism: an updated meta-analysis. Vessels 1997; 3: 4–11.
Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM . Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800–809.
Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182–186.
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Eng J Med 1995; 332: 1330–1335.
Laurent P, Dussarat GV, Bonal J, Jego C, Talard P, Bouchiat C et al. Low molecular weight heparins: a guide to their optimum use in pregnancy. Drugs 2002; 62: 463–477.
Forestier F, Daffos F, Capella-Pavlovsky M . Low molecular weight heparin does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34: 557–560.
Forestier F, Daffos F, Rainaut M, Toulemonde F . Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 1987; 57: 234.
Safety of lovenox in pregnancy. ACOG committee opinion no. 276. American college of obstetricians and gynecologists. Obstet Gynecol 2002; 100: 845–846.
Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 5: 668–672.
Ensom MH, Stephenson MD . Low-molecular-weight heparins in pregnancy. Pharmacotherapy 1999; 19: 1013–1025.
Bates SM, Greer IA, Hirsh J, Ginsberg JS . Use of antithrombotic agents during pregnancy. Chest 2004; 126: 627S–644S.
Horlocker TT, Wedel DJ . Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998; 23 (Suppl): 164–177.
Horlocker TT, Wedel DJ . Spinal and epidural blockade and perioperative low molecular weight heparin: smooth sailing on the titanic. Anesth Analg 1998; 86: 1153–1156.
Checketts MR, Wildsmith JAW . Central nerve block and thromboprophylaxis – is there a problem? Br J Anaesth 1999; 82: 164–167.
Jansen AJG, van Rhenen DJ, Steegers EAP, Duvekot JJ . Postpartum hemorrhage and transfusion of blood and blood components. Obstet Gynecol Surv 2005; 60: 663–671.
Nelson-Piercy C, Letsky EA, deSwiet M . Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1062–1068.
Ellison J, Walker ID, Greer IA . Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG 2000; 107: 1116–1121.
Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108: 1134–1140.
Rowan JA, McLintock C, Taylor RS, North RA . Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes, and monitoring. Aust N Z J Obstet Gynecol 2003; 43: 123–128.
Maslovitz S, Many A, Landsberg JA, Varon D, Lessing JB, Kupferminc MJ . The safety of low molecular weight heparin therapy during labor. J Matern Fetal Neonatl Med 2005; 17: 39–43.
Thromboembolism in pregnancy. ACOG practice bulletin no. 19. American College of Obstetricians and Gynecologists. Obstet Gynecol 2000; 96.
Brenner B, Bar J, Ellis M, Yarom I, Yohai D, Samueloff A, Live-Enox Investigators. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril 2005; 84: 770–773.
Acknowledgements
Poster presentation at the American College of Obstetricians and Gynecologists Annual Meeting in Washington DC, May 8, 2006.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kominiarek, M., Angelopoulos, S., Shapiro, N. et al. Low-molecular-weight heparin in pregnancy: peripartum bleeding complications. J Perinatol 27, 329–334 (2007). https://doi.org/10.1038/sj.jp.7211745
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7211745
Keywords
This article is cited by
-
Anticoagulant and antithrombotic drugs in pregnancy: what are the anesthetic implications for labor and cesarean delivery?
Journal of Perinatology (2011)